Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Doxycycline Host-directed Therapy to Improve Lung Function and Decrease Tissue Destruction in Pulmonary Tuberculosis: A Phase III Randomized Control Trial (Doxy-TB)

NCT05473520 is registered in ClinicalTrials.gov with National University Hospital, Singapore as lead sponsor.

NCT NCT05473520
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05473520 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Doxycycline Host-directed Therapy to Improve Lung Function and Decrease Tissue Destruction in Pulmonary Tuberculosis: A Phase III Randomized Control Trial (Doxy-TB)
Lead sponsor
National University Hospital, Singapore
Phase
Phase 3
Overall status
Recruiting
Start date
May 24, 2023
Completion date
January 31, 2030
Enrollment
150 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

acute coronary syndrome, pulmonary hypertension (diagnosis), tuberculosis